Targeted Oncology™ brings you Targeted Talks, a monthly podcast featuring discussions with academic and community oncologists surrounding advancements in cancer research and best practices for patient management.
June 15, 2022
In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.
May 17, 2022
In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.
April 15, 2022
In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.
March 16, 2022
In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.
February 15, 2022
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
December 15, 2021
In season 2, episode 10 of Targeted Talks, Sandra P. D'Angelo, MD, and Katherine Poruk, MD, discuss frontline treatment practices in the sarcoma space.
November 17, 2021
In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.
September 15, 2021
In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.
August 16, 2021
In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.
July 15, 2021
In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer